HRP20201224T1 - Sastavi i postupci za liječenje bolesti - Google Patents
Sastavi i postupci za liječenje bolesti Download PDFInfo
- Publication number
- HRP20201224T1 HRP20201224T1 HRP20201224TT HRP20201224T HRP20201224T1 HR P20201224 T1 HRP20201224 T1 HR P20201224T1 HR P20201224T T HRP20201224T T HR P20201224TT HR P20201224 T HRP20201224 T HR P20201224T HR P20201224 T1 HRP20201224 T1 HR P20201224T1
- Authority
- HR
- Croatia
- Prior art keywords
- composition
- subject
- compositions
- methods
- treating diseases
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 5
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims 2
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 239000013646 rAAV2 vector Substances 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims 1
- 108010044052 Desmin Proteins 0.000 claims 1
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 claims 1
- 206010053185 Glycogen storage disease type II Diseases 0.000 claims 1
- 102000055120 MEF2 Transcription Factors Human genes 0.000 claims 1
- 108010018650 MEF2 Transcription Factors Proteins 0.000 claims 1
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 108010028144 alpha-Glucosidases Proteins 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 1
- 201000004502 glycogen storage disease II Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16644—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
Claims (3)
1. Sastav za upotrebu u liječenju Pompeove bolesti, koja se sastoji od vektora rAAV2/8, pri čemu rAAV2/8 vektor sadrži heterolognu molekulu nukleinske kiseline koja kodira kiselu α-glukozidazu, pri čemu je heterologna nukleinska kiselina operativno povezana s promotorom gena za dezmin, pojačivačkim elementom pojačivačkog faktora 2 specifičnim za miocit i MyoD pojačivačkim elementom, pri čemu se sastav daje subjektu kome je to potrebno intramuskularnom, intratorakalnom, intraspinalnom, intratekalnom, intracisternalnom ili intravenskom injekcijom.
2. Sastav za upotrebu prema patentnom zahtjevu 1, pri čemu se subjektu dalje daje inhibitor acetilholinesteraze.
3. Sastav za upotrebu prema patentnom zahtjevu 1 ili 2, gdje je subjekt čovjek.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/527,350 US20120322861A1 (en) | 2007-02-23 | 2012-06-19 | Compositions and Methods for Treating Diseases |
EP17184780.9A EP3292875B1 (en) | 2012-06-19 | 2013-06-19 | Compositions and methods for treating diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20201224T1 true HRP20201224T1 (hr) | 2020-11-13 |
Family
ID=49769685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20201224TT HRP20201224T1 (hr) | 2012-06-19 | 2020-08-04 | Sastavi i postupci za liječenje bolesti |
Country Status (24)
Country | Link |
---|---|
US (2) | US10912804B2 (hr) |
EP (4) | EP4124346A3 (hr) |
JP (1) | JP2015523998A (hr) |
KR (1) | KR20150020250A (hr) |
CN (1) | CN104619354A (hr) |
AU (1) | AU2013277215A1 (hr) |
BR (1) | BR112014031788A2 (hr) |
CA (1) | CA2875523A1 (hr) |
CL (1) | CL2014003464A1 (hr) |
CY (1) | CY1123485T1 (hr) |
DK (1) | DK3292875T3 (hr) |
ES (1) | ES2813558T3 (hr) |
HK (1) | HK1209633A1 (hr) |
HR (1) | HRP20201224T1 (hr) |
HU (1) | HUE051632T2 (hr) |
IL (1) | IL236298A0 (hr) |
LT (1) | LT3292875T (hr) |
MX (1) | MX2014015985A (hr) |
PL (1) | PL3292875T3 (hr) |
PT (1) | PT3292875T (hr) |
RS (1) | RS61055B1 (hr) |
RU (1) | RU2015101276A (hr) |
SI (1) | SI3292875T1 (hr) |
WO (1) | WO2013192317A2 (hr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120322861A1 (en) | 2007-02-23 | 2012-12-20 | Barry John Byrne | Compositions and Methods for Treating Diseases |
DK3292875T3 (en) | 2012-06-19 | 2020-08-03 | Univ Florida | Compositions and methods for treating diseases |
JP2016523835A (ja) * | 2013-05-15 | 2016-08-12 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 中枢神経系へのアデノ随伴ウイルスを介した遺伝子導入 |
MX2018005332A (es) * | 2015-11-06 | 2018-11-09 | Crispr Therapeutics Ag | Materiales y metodos para tratamiento de la enfermedad de almacenamiento de glucogeno tipo 1a. |
EP3293259A1 (en) | 2016-09-12 | 2018-03-14 | Genethon | Acid-alpha glucosidase variants and uses thereof |
IL299325A (en) | 2016-09-12 | 2023-02-01 | Inst Nat Sante Rech Med | Variants of acid alpha glucosidase and their uses |
KR20200015932A (ko) | 2017-06-07 | 2020-02-13 | 리제너론 파마슈티칼스 인코포레이티드 | 효소 내재화를 위한 조성물 및 방법 |
SG11202002457RA (en) | 2017-09-22 | 2020-04-29 | Univ Pennsylvania | Gene therapy for treating mucopolysaccharidosis type ii |
JP6567012B2 (ja) * | 2017-09-28 | 2019-08-28 | キヤノン株式会社 | 情報処理装置、情報処理方法、およびプログラム |
JP7134444B2 (ja) * | 2018-01-26 | 2022-09-12 | 国立大学法人徳島大学 | テイ-サックス病及びザンドホッフ病治療用の新規アデノ随伴ウイルスビリオン |
CN111936621A (zh) * | 2018-02-05 | 2020-11-13 | 奥登茨治疗公司 | 转录调控元件和它的用途 |
CN111902539A (zh) * | 2018-02-07 | 2020-11-06 | 吉尼松公司 | 杂合调控元件 |
KR20220105643A (ko) * | 2019-10-25 | 2022-07-27 | 오덴테스 테라퓨틱스, 인크. | 글리코겐 축적 장애를 치료하기 위한 조성물 및 방법 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US6451600B1 (en) | 1989-12-22 | 2002-09-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
US5869305A (en) | 1992-12-04 | 1999-02-09 | The University Of Pittsburgh | Recombinant viral vector system |
WO1995011640A1 (en) | 1993-10-26 | 1995-05-04 | Howmedica Inc. | Prosthesis with integral proximal spacer |
US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
US6001650A (en) | 1995-08-03 | 1999-12-14 | Avigen, Inc. | High-efficiency wild-type-free AAV helper functions |
US5962313A (en) | 1996-01-18 | 1999-10-05 | Avigen, Inc. | Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme |
US6083725A (en) | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
US6426208B1 (en) | 1999-11-12 | 2002-07-30 | Harbor-Ucla Research And Education Institute | Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof |
DE60231975D1 (de) * | 2001-05-24 | 2009-05-28 | Genzyme Corp | Muskelspezifische expressionsvektoren |
EP3339430A1 (en) | 2001-12-17 | 2018-06-27 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses thereof |
EP1481067A1 (en) | 2002-03-04 | 2004-12-01 | Transgene S.A. | Expression cassette for persistence of expression of a gene of interest in muscle cells |
US7858367B2 (en) | 2002-04-30 | 2010-12-28 | Duke University | Viral vectors and methods for producing and using the same |
WO2003092598A2 (en) * | 2002-04-30 | 2003-11-13 | University Of Florida | Treatment for pompe disease |
AU2003302724A1 (en) * | 2002-08-13 | 2004-07-09 | Mcivor, Scott, R. | Methods of using vectors to treat metabolic disorders |
ATE521701T1 (de) | 2003-01-22 | 2011-09-15 | Univ Duke | Verbesserte konstrukte zur expression lysosomaler polypeptide |
EP1668110A2 (en) * | 2003-08-21 | 2006-06-14 | Q Therapeutics, Inc. | Genetically modified somatic cells for sustained secretion of lysosomal proenzymes deficient in lysosomal storage disorders |
WO2005049850A2 (en) * | 2003-11-14 | 2005-06-02 | University Of Washington | Compositions and methods for systemic nucleic acid sequence delivery |
JP2007513968A (ja) | 2003-12-12 | 2007-05-31 | ウイスコンシン アラムニ リサーチ ファンデーション | 哺乳動物神経細胞へのsiRNAのデリバリー |
WO2005118611A2 (en) * | 2004-01-23 | 2005-12-15 | The Trustees Of The University Of Pennsylvania | Microutrophin and uses thereof |
WO2005077333A2 (en) | 2004-02-10 | 2005-08-25 | University Of Florida Research Foundation, Inc. | Gel-based delivery of recombinant adeno-associated virus vectors |
CA2553955C (en) * | 2004-02-10 | 2012-08-28 | Zystor Therapeutics, Inc. | Acid alpha-glucosidase and fragments thereof |
AU2005296063A1 (en) * | 2004-10-05 | 2006-04-27 | University Of Georgia Research Foundation, Inc. | Neuronal progenitors from feeder-free human embryonic stem cell culture |
EP1828390B1 (en) | 2004-12-15 | 2012-06-13 | The University Of North Carolina At Chapel Hill | Chimeric vectors |
PL1874282T3 (pl) | 2005-04-06 | 2011-04-29 | Adamas Pharmaceuticals Inc | Sposoby i kompozycje do leczenia zaburzeń OUN |
WO2007056614A1 (en) | 2005-11-14 | 2007-05-18 | Merial Limited | Gene therapy for renal failure |
WO2007089632A2 (en) * | 2006-01-27 | 2007-08-09 | The University Of North Carolina At Chapel Hill | Heparin and heparan sulfate binding chimeric vectors |
DK1988823T3 (en) | 2006-02-09 | 2018-12-03 | Genzyme Corp | SLOW INTRAVENTRICULAR ADMINISTRATION |
WO2008058269A2 (en) * | 2006-11-09 | 2008-05-15 | Foldrx Pharmaceuticals, Inc. | Compounds and methods for modulating protein trafficking |
CN101636200A (zh) * | 2006-11-13 | 2010-01-27 | 齐斯特治疗公司 | 用于治疗庞贝氏症的方法 |
US20120322861A1 (en) | 2007-02-23 | 2012-12-20 | Barry John Byrne | Compositions and Methods for Treating Diseases |
EP2132309A4 (en) | 2007-02-23 | 2011-01-05 | Univ Florida | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES RELATED TO GLYCOGEN STORAGE |
EP2058401A1 (en) * | 2007-10-05 | 2009-05-13 | Genethon | Widespread gene delivery to motor neurons using peripheral injection of AAV vectors |
EP2430442B1 (en) * | 2009-05-14 | 2015-04-01 | Oatmeal Biotechnologies Group, L.L.C. | Platform technologies for spontaneously occurring diseases |
CN102548986A (zh) * | 2009-06-05 | 2012-07-04 | 链接医药公司 | 氨基吡咯烷酮衍生物及其用途 |
US20130166313A1 (en) | 2010-04-02 | 2013-06-27 | Shire Human Genetic Therapies, Inc. | Systems and methods for managing treatment of an orphan disease |
PT3486320T (pt) | 2010-04-23 | 2022-03-30 | Univ Florida | Composições de ciclase raav-guanilato e métodos para tratar a amaurose congénita 1 de leber (acl1) |
US8679478B2 (en) * | 2010-10-04 | 2014-03-25 | Duke University | Methods of lysosomal storage disease therapy |
US20120141420A1 (en) * | 2010-11-30 | 2012-06-07 | Sygnis Bioscience Gmbh & Co. Kg | Targeted delivery of g-csf for the treatment of amyotrophic lateral sclerosis |
WO2013177367A2 (en) | 2012-05-23 | 2013-11-28 | The Johns Hopkins University | Compounds and methods of use thereof for treating neurodegenerative disorders |
DK3292875T3 (en) | 2012-06-19 | 2020-08-03 | Univ Florida | Compositions and methods for treating diseases |
-
2013
- 2013-06-19 DK DK17184780.9T patent/DK3292875T3/da active
- 2013-06-19 CA CA2875523A patent/CA2875523A1/en not_active Abandoned
- 2013-06-19 SI SI201331755T patent/SI3292875T1/sl unknown
- 2013-06-19 MX MX2014015985A patent/MX2014015985A/es unknown
- 2013-06-19 ES ES17184780T patent/ES2813558T3/es active Active
- 2013-06-19 EP EP22151622.2A patent/EP4124346A3/en active Pending
- 2013-06-19 LT LTEP17184780.9T patent/LT3292875T/lt unknown
- 2013-06-19 WO PCT/US2013/046592 patent/WO2013192317A2/en active Application Filing
- 2013-06-19 EP EP17184780.9A patent/EP3292875B1/en active Active
- 2013-06-19 EP EP13807500.7A patent/EP2861263B1/en active Active
- 2013-06-19 AU AU2013277215A patent/AU2013277215A1/en not_active Abandoned
- 2013-06-19 PL PL17184780T patent/PL3292875T3/pl unknown
- 2013-06-19 HU HUE17184780A patent/HUE051632T2/hu unknown
- 2013-06-19 BR BR112014031788A patent/BR112014031788A2/pt active Search and Examination
- 2013-06-19 EP EP20167347.2A patent/EP3818991A3/en not_active Withdrawn
- 2013-06-19 RU RU2015101276A patent/RU2015101276A/ru not_active Application Discontinuation
- 2013-06-19 RS RS20200992A patent/RS61055B1/sr unknown
- 2013-06-19 PT PT171847809T patent/PT3292875T/pt unknown
- 2013-06-19 KR KR1020157001321A patent/KR20150020250A/ko not_active Application Discontinuation
- 2013-06-19 JP JP2015518552A patent/JP2015523998A/ja active Pending
- 2013-06-19 CN CN201380043921.XA patent/CN104619354A/zh active Pending
-
2014
- 2014-12-16 IL IL236298A patent/IL236298A0/en unknown
- 2014-12-19 CL CL2014003464A patent/CL2014003464A1/es unknown
-
2015
- 2015-10-22 HK HK15110424.8A patent/HK1209633A1/xx unknown
-
2016
- 2016-04-01 US US15/088,167 patent/US10912804B2/en active Active
-
2020
- 2020-08-04 HR HRP20201224TT patent/HRP20201224T1/hr unknown
- 2020-08-17 CY CY20201100768T patent/CY1123485T1/el unknown
- 2020-12-31 US US17/139,097 patent/US20210145906A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3292875A1 (en) | 2018-03-14 |
US20170028002A1 (en) | 2017-02-02 |
WO2013192317A2 (en) | 2013-12-27 |
HUE051632T2 (hu) | 2021-03-29 |
EP4124346A2 (en) | 2023-02-01 |
EP4124346A3 (en) | 2023-04-19 |
ES2813558T3 (es) | 2021-03-24 |
JP2015523998A (ja) | 2015-08-20 |
IL236298A0 (en) | 2015-02-26 |
US10912804B2 (en) | 2021-02-09 |
EP2861263B1 (en) | 2017-12-06 |
CN104619354A (zh) | 2015-05-13 |
EP3818991A3 (en) | 2021-07-14 |
BR112014031788A2 (pt) | 2017-06-27 |
DK3292875T3 (en) | 2020-08-03 |
EP3818991A2 (en) | 2021-05-12 |
SI3292875T1 (sl) | 2020-08-31 |
LT3292875T (lt) | 2020-08-25 |
PT3292875T (pt) | 2020-08-31 |
RU2015101276A (ru) | 2016-08-10 |
HK1209633A1 (en) | 2016-04-08 |
EP2861263A4 (en) | 2016-04-13 |
KR20150020250A (ko) | 2015-02-25 |
EP2861263A2 (en) | 2015-04-22 |
CY1123485T1 (el) | 2022-03-24 |
CL2014003464A1 (es) | 2015-06-12 |
AU2013277215A1 (en) | 2015-02-05 |
CA2875523A1 (en) | 2013-12-27 |
PL3292875T3 (pl) | 2020-11-16 |
RS61055B1 (sr) | 2020-12-31 |
MX2014015985A (es) | 2015-07-21 |
US20210145906A1 (en) | 2021-05-20 |
EP3292875B1 (en) | 2020-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20201224T1 (hr) | Sastavi i postupci za liječenje bolesti | |
EA201791417A1 (ru) | Супрессия гена гентингтина, индуцированная рнк-интерференцией | |
BR112014022000A8 (pt) | compostos à base de pirazol[1,5-a]pirimidina, seu uso e composições que os compreende | |
PE20150968A1 (es) | Nuevos acidos indaniloxi dihidrobenzofuranil aceticos | |
GB2527450A (en) | Compositions and methods of nucleic acid-targeting nucleic acids | |
MX2015015412A (es) | Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica. | |
TN2014000079A1 (en) | Selective and reversible inhibitors of ubiquitin specific protease 7 | |
MX2017009767A (es) | Nuevas proteínas específicas para la angiogénesis. | |
CY1117543T1 (el) | Αναστολεις βητα-σεκρετασης | |
IN2014CN00953A (hr) | ||
EA201391394A1 (ru) | Композиции и способы ингибирования экспрессии генов вируса гепатита в | |
BR112014026176A2 (pt) | dipiridilaminas substituídas e usos das mesmas | |
BR112016002753A2 (pt) | anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos | |
BR112012007322A2 (pt) | composto de 2-piridona usados como inibidores de neutrófilo elastase | |
MX369726B (es) | Polipéptidos con actividad proteasa. | |
BR112013001753A2 (pt) | método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada. | |
MX2016008518A (es) | Micro-acido ribonucleico (micro-arn) concordante artificial para controlar la expresion genetica y uso del mismo. | |
BRPI0916464A2 (pt) | derivados triazolo(4,3-a) piridina, o respectivo processo de preparo, a respectiva aplicação como medicamentos, composições farmacêuticas e utilização notadamente como inibidores de met | |
WO2014053401A3 (en) | Method of improving plant health | |
MX2019011317A (es) | Elementos reguladores de plantas y sus usos. | |
MX2019011818A (es) | Elementos reguladores de plantas y sus usos. | |
WO2014122161A3 (en) | Use of polypeptides having protease activity in animal feed | |
WO2013189972A3 (en) | Use of polypeptides having protease activity in animal feed and detergents | |
BR112018013033A2 (pt) | compostos de indolinonas e seu uso no tratamentod de doenças fibróticas | |
EA201590264A1 (ru) | Экспрессионные векторы, содержащие химерные цитомегаловирусные промоторные и энхансерные последовательности |